55P Molecular risk factors for distant metastases in premenopausal patients with HR+/HER2- EBC

Abstract

Breast cancer ranks first in females, concerning cancer incidence and mortality. Breast cancer in premenopausal patients (vs. postmenopausal patients) has unique gene expression patterns, rendering molecular drivers of tumor progression in premenopausal women of particular clinical interest. Our research focused on premenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (EBC), and the molecular drivers of distant metastases after standard adjuvant treatment.